Integra LifeSciences Holdings Corporation — Form 10-Q Summary
Business Context and Reporting Period
Integra is a global medical technology company serving neurosurgery, orthopedics, spine, reconstructive surgery, and general surgery markets. This unaudited Form 10-Q covers the three months ended March 31, 2014, compared with the three months ended March 31, 2013. The company reported five segments: U.S. Neurosurgery, U.S. Instruments, U.S. Extremities, U.S. Spine and Other, and International.
On January 15, 2014, Integra acquired Confluent Surgical from Covidien for an aggregate purchase price of $255.9 million, including $231.0 million of cash, a $4.0 million supply-agreement prepayment, and $20.9 million of estimated contingent consideration. The acquisition added surgical sealant and adhesion-barrier products, including DuraSeal.
Key Financial Metrics
| Metric | Q1 2014 | Q1 2013 | Change |
|---|---|---|---|
| Total revenue | $215.1 million | $196.7 million | Up $18.4 million, or 9% |
| Gross profit | $132.7 million | $117.0 million | Up $15.6 million |
| Gross margin | 61.7% | 59.5% | Up 220 basis points |
| Operating income (loss) | $8.7 million | $(2.2) million | Improved $10.9 million |
| Net income (loss) | $2.2 million | $(6.0) million | Improved $8.2 million |
| Diluted EPS | $0.07 | $(0.22) | Improved $0.29 |
| Operating cash flow | $11.3 million | $7.8 million | Up $3.4 million |
Operating margin was approximately 4.1% in Q1 2014 versus negative 1.1% in Q1 2013. The effective tax rate was 44.5%, compared with 23.7% in the prior-year quarter; management attributed the increase primarily to state tax audit settlements, a higher proportion of U.S. earnings, and the absence of a prior-year French tax benefit. Management expects a full-year 2014 effective tax rate of approximately 23% to 24%.
At March 31, 2014, cash and cash equivalents were $129.0 million, compared with $120.6 million at December 31, 2013. Working capital was $422.9 million. Cash used in investing activities was $246.3 million, including $235.0 million for the Confluent acquisition and $11.3 million of capital expenditures. Financing activities provided $243.2 million, principally from borrowings used to fund the acquisition.
Debt included $421.9 million outstanding under the senior credit facility and $230.0 million principal amount of 1.625% convertible senior notes due December 2016. The credit facility had approximately $178.1 million of additional borrowing capacity, and the company was in compliance with its financial covenants. The weighted-average interest rate on credit-facility borrowings was 1.7%.
Material Changes Versus the Prior Comparable Period
- Revenue increased 9%, led by U.S. Neurosurgery, International operations, and the acquired DuraSeal product line.
- U.S. Neurosurgery revenue increased 39% to $54.4 million, including $10.6 million of DuraSeal revenue. International revenue increased 11% to $51.0 million.
- U.S. Spine and Other revenue declined 6% to $41.1 million, primarily because of continued weakness in spine hardware and lost private-label business related to prior-year recall-related supply disruptions.
- Orthopedics revenue declined to $87.2 million from $90.3 million, while Neurosurgery revenue increased to $84.4 million from $63.2 million.
- Gross margin improved primarily because 2013 recall and manufacturing-remediation costs did not recur at the same level, Duragen products were no longer subject to the recall, and DuraSeal products carried favorable margins.
- Operating expenses increased 4% to $123.9 million. Selling, general and administrative expense increased because of acquisition-related bank fees, transition-services costs, higher commissions, and ERP-related licensing fees.
- The company retrospectively changed its accounting for the medical device excise tax. The tax is now recorded in selling, general and administrative expense when the first sale occurs rather than through inventory and cost of goods sold. Prior-period amounts were revised.
- Goodwill increased to $367.6 million and net intangible assets increased to $429.4 million, principally because of the Confluent acquisition.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management expects full-year 2014 gross margin of approximately 61% to 62%, supported by product mix, DuraSeal growth, and improved manufacturing yields.
- Research and development spending is targeted at approximately 6% of full-year revenue.
- 2014 capital expenditures are expected to be $45 million to $55 million, primarily for regenerative-medicine manufacturing capacity, existing facilities, ERP implementation, and orthopedic instrument kits. The company also expects to build inventory before facility consolidations planned for the second half of 2014.
- Reported Q1 2014 income included $15.9 million of identified special charges, including ERP implementation, structural optimization, acquisition-related costs, employee termination charges, impairment charges, and non-cash convertible-debt interest. Management cautioned that some special charges may recur.
- A regulatory event resulted in a $0.6 million impairment of an acquired Confluent technology asset. The company also recorded a $128,000 increase in the fair value of contingent acquisition consideration.
- The company continued remediation of FDA quality-system observations at its Andover, England and Añasco, Puerto Rico facilities. Q1 2014 remediation costs were $0.1 million, compared with $2.1 million in Q1 2013; management expects additional but lower remediation spending during 2014.
- The company is cooperating with a U.S. Attorney’s Office investigation concerning alleged improper billing by sales representatives in its Extremities Reconstruction division. Integra stated that it is not a subject or target of the investigation and awaits the government’s disposition.
- A licensor has indicated that it intends to terminate an international extremities-product license effective October 20, 2014. Products sold under the license generated approximately $5.5 million of revenue in 2013. Potential claims and the ultimate financial effect are uncertain.
- Interest-rate and foreign-currency exposure remain material. A one-percentage-point change in interest rates would affect annual interest expense on the unhedged debt by approximately $3.1 million.
- On April 29, 2014, the company announced that Glenn G. Coleman would become chief financial officer and principal accounting officer after the Form 10-Q filing. John B. Henneman would become chief administrative officer, and the company expects severance obligations under his employment agreement.
Most Important Facts for Investors to Verify
- Whether Confluent Surgical integration, product transition, regulatory approvals, and contingent consideration develop as expected.
- Whether the projected 61% to 62% full-year gross margin is achieved without further material quality, recall, or remediation costs.
- Debt repayment capacity, leverage-covenant compliance, and the impact of the $235.0 million acquisition borrowing on future interest expense.
- The outcome of the U.S. Attorney’s investigation and the potential effect of the international license termination.
- Progress in resolving FDA quality-system observations and the related risk of additional remediation, product restrictions, recalls, or impairment charges.
- Whether revenue weakness in U.S. Spine and Other reverses and whether DuraSeal and other neurosurgery products sustain current growth.
- The effect of the retrospective medical device excise-tax accounting change when comparing reported historical results.